HOXD13 and plasma cell myeloma: As shown in Fig. 4, the sPD-1 level was found to be significantly higher in plasma samples from patients with non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), ovarian cancer (OVC), Multiple Myeloma (MM), and acute myeloid leukaemia (AML) than that detected in healthy donors.